This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Progressive Systemic Sclerosis진행성 전신경화증 (진행성전신경화증)

Contents and key points
ItemDetails
A. Classification codesICD-10: M34.0 (progressive systemic sclerosis) | Special Copayment Reduction: V138 (rare disease)
B. Synonyms—
C. Adult onsetLikelihood of first onset in adulthood: very high — progressive systemic sclerosis is typically first diagnosed in adults in their 30s–50s, beginning with Raynaud phenomenon, followed sequentially by skin sclerosis and visceral involvement. Pediatric onset is rare, accounting for less than 10% of the total, and most patients first notice symptoms in adulthood.
1. History1753 first described by Curzio → 1847 Gintrac named it 'scleroderma' → 1945 Goetz proposed systemic classification → 1980 ACR preliminary classification criteria published → 2013 revised ACR/EULAR classification criteria established.
2. CausesCombined etiology of autoimmunity, vascular injury, and fibrosis. Environmental factors (silica, organic solvents, radiation), genetic predisposition (HLA, IRF5, STAT4, etc.), infectious triggers. Exact single cause unknown.
3. GeneticsPolygenic complex inheritance. HLA-DRB1*11:04, HLA-DPB1*13:01 risk alleles. Associations with IRF5, STAT4, CD247, BLK, BANK1 SNPs. Associations between autoantibodies (anti-Scl-70, anti-RNAP III, anti-fibrillarin) and genotype.
4. General epidemiologyPrevalence about 100–300/1,000,000. Female:male = 3–5:1. Most common in the 30s–50s. About 3,000–5,000 estimated registered in Korean rare disease registry. Severe course in African Americans.
5. PathophysiologyVascular endothelial injury → T-cell·B-cell activation → autoantibodies → excess secretion of TGF-β, CTGF, PDGF → fibroblast activation → excess collagen deposition → skin·visceral fibrosis.
6. SymptomsRaynaud phenomenon, skin sclerosis (progressing from hands·face→trunk), esophageal dysmotility (dysphagia·reflux), interstitial lung disease (dyspnea), pulmonary arterial hypertension, scleroderma renal crisis, cardiac involvement.
7. SignsFinger swelling·sclerosis, ischemic digital tip ulcers, telangiectasia, reduced facial wrinkles, limited mouth opening, nailfold capillaroscopy abnormalities, basal lung crackles, accentuated P2 in PAH.
8. ScreeningIn patients with Raynaud phenomenon, nailfold capillaroscopy, ANA screening, and anti-Scl-70·anti-RNAP III·anti-fibrillarin antibody tests. In high-risk groups, screening with pulmonary function tests·chest HRCT·echocardiography.
9. Diagnosis2013 ACR/EULAR classification criteria (point-based): skin thickening proximal to the MCPs of both hands 9 points, fingertip lesions·ulcers, telangiectasia, capillaroscopy abnormalities, PAH/ILD, Raynaud phenomenon, SSc-related autoantibodies. Total of 9 points or more confirms.
10. TreatmentOrgan-specific treatment: ILD (mycophenolate, cyclophosphamide, nintedanib), PAH (endothelin receptor antagonists, PDE-5 inhibitors, riociguat, prostacyclin), Raynaud phenomenon (CCB, bosentan). Skin: methotrexate, mycophenolate. Renal crisis: ACE inhibitors.
11. Prognosis5-year survival of dcSSc (diffuse type) about 70–80%, 10-year about 55–70%. Main causes of death: ILD, PAH, cardiac involvement. Anti-RNAP III antibody: rapid skin progression, risk of renal crisis. Prognosis improves with early detection·organ-specific treatment.
12. PreventionPrimary: reduce exposure to environmental risk factors (silica, organic solvents). Secondary: early diagnosis at the Raynaud phenomenon stage·autoantibody screening. Tertiary: early detection of ILD·PAH with regular pulmonary function tests·echocardiography, smoking cessation, cold avoidance, skin moisturizing, maintaining adequate nutrition.
13. Referencesvan den Hoogen F, et al. 2013 classification criteria for SSc. ACR/EULAR. Arthritis Rheum. 2013 … and 9 other papers

1. History

The history of Progressive Systemic Sclerosis (PSS) begins in 1753, when the 18th-century Italian physician Carlo Curzio described a young female patient whose skin was progressively hardening. Curzio reported that he treated this patient with hot baths, mercury vapor, bloodletting, and other measures and observed some relief, and this is recognized as the first detailed medical record of systemic sclerosis. Later, in 1836, the French physician Gintrac first used the name 'scleroderma (sclérodermie)', and in 1847 the term became formally established in the medical literature.

From the late 19th to the early 20th century, visceral involvement in systemic sclerosis gradually began to be recognized. In 1898, von Nothnagel of Germany described esophageal involvement, and in the 1920s reports of pulmonary and renal involvement followed. In 1945, the South African physician Goetz proposed the comprehensive name 'progressive systemic sclerosis', on the grounds that the skin sclerosis involves multiple organs throughout the body at the same time, and this name was used internationally for decades thereafter.

From the mid-20th century, autoantibody research brought innovation to diagnosis and understanding of the pathophysiology. After the first detection of antinuclear antibodies (ANA) in 1958, the anti-Scl-70 (anti-topoisomerase I) antibody was discovered by Tan et al. in 1975. In 1980, the American College of Rheumatology (ACR) published preliminary classification criteria for systemic sclerosis, standardizing clinical research. In the 1980s, disease-specific autoantibodies such as anti-RNA polymerase III (anti-RNAP III), anti-fibrillarin, and anti-PM-Scl antibodies were discovered one after another and began to be used for subtype classification and prognostic prediction.

In 1988, LeRoy, Medsger, and others proposed a system classifying the disease by extent of skin involvement into diffuse cutaneous systemic sclerosis (dcSSc) and limited cutaneous systemic sclerosis (lcSSc), and this classification is still used as the clinical standard. In 2013, the ACR and the European League Against Rheumatism (EULAR) jointly published revised classification criteria; adopting a point-based system that gives the highest weight to skin thickening proximal to the metacarpophalangeal joints of both hands and adds up autoantibodies, capillaroscopy abnormalities, and findings of visceral involvement, they greatly improved diagnostic sensitivity and specificity. In Korea, systemic sclerosis has been designated for rare disease Special Copayment Reduction (V138) since the 2010s, reducing patients' medical cost burden, and building of a domestic cohort and development of treatment guidelines are under way, centered on the systemic sclerosis study group of the Korean College of Rheumatology.

In the history of treatment, in the 1990s ACE inhibitors showed a dramatic effect in preventing and treating scleroderma renal crisis, greatly reducing mortality from renal failure. Since the 2000s, clinical studies of cyclophosphamide for interstitial lung disease (ILD) (SLS I·II) and the development of endothelin receptor antagonists (bosentan, ambrisentan) and PDE-5 inhibitors (sildenafil, tadalafil) for pulmonary arterial hypertension (PAH) have greatly improved the prognosis of systemic sclerosis-associated PAH. In 2019, nintedanib became the first FDA-approved treatment for SSc-ILD, and since then autologous hematopoietic stem cell transplantation (ASCT) has attracted attention as a strategy to reverse skin and visceral involvement in selected patients.


2. Causes

The cause of progressive systemic sclerosis is understood not as a single factor but as a multifactorial etiology in which genetic predisposition, environmental triggers, immune abnormalities, vascular injury, and fibrotic responses are intricately intertwined. The three core axes of the etiology can be summarized as ① vascular injury and abnormal vascular responses, ② autoimmune activation, and ③ excessive fibrosis due to fibroblast activation.

Vascular injury: The earliest pathological change is endothelial cell injury of small vessels, particularly capillaries and arterioles. Injured endothelial cells lose the balance of secretion of vasoactive substances (endothelin-1, prostacyclin, nitric oxide), leading to vasoconstriction, vascular occlusion, and reduced angiogenesis. Raynaud phenomenon is the earliest clinical expression of this abnormal vascular reactivity. As vascular lesions progress, capillaries are lost and ischemia-reperfusion injury repeats, forming a vicious cycle in which reactive oxygen species (ROS) cause further endothelial injury.

Autoimmune abnormalities: Both adaptive and innate immune cells, including T cells, B cells, natural killer cells (NK cells), and dendritic cells, are involved in the etiology. A Th2 skew of CD4+ T helper cells increases the secretion of profibrotic cytokines such as IL-4 and IL-13. Evidence is accumulating that autoantibodies produced by B-cell activation play a direct pathogenic role beyond being simple diagnostic markers. Anti-Scl-70 (anti-topoisomerase I) antibodies are associated with diffuse skin involvement and ILD, anti-RNAP III antibodies with rapid skin progression and renal crisis, and anti-fibrillarin antibodies with severe skin involvement and cardiac·pulmonary involvement.

Fibrosis: TGF-β1 is the key mediator of fibrosis, activating fibroblasts and inducing excess production of collagen (especially types I and III), fibronectin, and proteoglycans. Activated fibroblasts differentiate into myofibroblasts and continuously overproduce·accumulate extracellular matrix (ECM). CTGF (connective tissue growth factor), as a downstream mediator of TGF-β, amplifies fibrosis. PDGF (platelet-derived growth factor) stimulates fibroblast proliferation, and cytokines such as IL-6 and IL-17 also participate in the fibrotic circuit.

Environmental factors: Occupational exposure to silica (silicon dioxide) dust is a clearly established environmental risk factor that increases the risk of systemic sclerosis several-fold. Organic solvents (toluene, xylene, ketones, trichloroethylene), epoxy resins, and aromatic hydrocarbons have also been reported to be associated with onset. An association with breast implants (silicone gel) was debated for decades, but large epidemiological studies have not currently established a causal relationship. Localized skin sclerosis (radiation-induced scleroderma) can develop after radiation therapy, and some drugs (bleomycin, pentazocine, contaminated L-tryptophan products) also cause scleroderma-like syndromes. As infectious factors, it has been hypothesized that cytomegalovirus (CMV) and Epstein-Barr virus (EBV) can trigger autoimmune responses via molecular mimicry.


3. Genetics

Systemic sclerosis is a polygenic autoimmune disease in which multiple genetic variants interact in combination, rather than a single-gene defect. An increased risk associated with family history (monozygotic twin concordance about 4.7%) has been confirmed, but genetic factors alone cannot explain onset, and interaction with environmental and epigenetic factors is essential.

HLA associations: Major histocompatibility complex (MHC) genes, central to the immune response, and particularly HLA class II alleles, play an important role in susceptibility to systemic sclerosis. HLA-DRB1*11:04 is most strongly associated as a risk allele in patients of European ancestry, and HLA-DPB1*13:01 has also been identified as a susceptibility allele. The associated HLA alleles differ by autoantibody type: anti-Scl-70 antibodies are associated with HLA-DRB1*11:04 and DRB1*15:02, anti-RNAP III antibodies with HLA-DRB1*01:01 and DRB1*04:01, and anti-fibrillarin antibodies with HLA-DRB1*11:03. HLA-DRB1*07:01 is reported as a protective allele.

Non-HLA genetic associations: Genome-wide association studies (GWAS) have shown that variants in genes related to immune regulation, signal transduction, and apoptosis are associated with susceptibility to systemic sclerosis. IRF5 (Interferon regulatory factor 5) variants promote activation of the type I interferon response, amplifying autoimmune responses. STAT4 variants affect the Th1/Th2 balance via the interferon-γ pathway and show a stronger association in anti-Scl-70 antibody-positive patients. CD247 (TCRζ chain) variants are related to abnormal T-cell receptor signal transduction. Variants of BLK and BANK1, genes regulating B-cell activation, have also been identified as susceptibility genes shared with several autoimmune diseases.

Epigenetics: Evidence is accumulating that, in addition to genetic sequence variants, epigenetic changes such as DNA methylation, histone modification, and noncoding RNAs (miRNA, lncRNA) contribute to the pathophysiology of systemic sclerosis. In systemic sclerosis fibroblasts, promoter hypermethylation of antifibrotic genes (e.g., FLI1) and hypomethylation of profibrotic genes are observed. MicroRNAs such as miR-21, miR-29, and miR-155 are involved in regulating the TGF-β signaling pathway and collagen synthesis. Because these epigenetic changes may be reversible, they could become targets of treatment strategies based on epigenome editing.

Autoantibodies and genotype: Autoantibody type is closely associated with clinical subtype, pattern of organ involvement, and prognosis, and these associations partly reflect the distribution of specific HLA and non-HLA genotypes. Therefore, autoantibody testing is used beyond a simple diagnostic tool as an indicator indirectly reflecting genetic background and the expected clinical course. Clinically, anti-Scl-70 positivity suggests dcSSc and severe ILD; anti-RNAP III positivity, rapid skin progression and renal crisis; and anti-fibrillarin (U3-RNP) positivity, a high risk of PAH and cardiac involvement.


4. General epidemiology

Progressive systemic sclerosis is a rare autoimmune disease, with a reported worldwide prevalence of about 100–300 per million population and an annual incidence of about 5–20 per million. However, figures vary greatly by region, race, and study method. Prevalence is highest in North America, especially among African American women (about 400/million), and incidence tends to be slightly lower in East Asian countries, including Japan and Korea, than in Europe. Very high prevalence has been reported in an indigenous (Native American, Choctaw) population, suggesting a genetic clustering effect.

Sex and age distribution: Systemic sclerosis occurs at a markedly higher frequency in women, with an overall female:male ratio of about 3–5:1. However, male patients tend to have more pulmonary arterial hypertension and cardiac involvement and a poorer prognosis. Onset is concentrated in the 30s–50s, and pediatric onset (juvenile SSc) is rare at about 3–10% of the total. Because the risk of onset is high in premenopausal women, an immunomodulatory role of sex hormones has been proposed.

Distribution of clinical subtypes: The ratio of diffuse cutaneous systemic sclerosis (dcSSc) to limited cutaneous systemic sclerosis (lcSSc) varies between studies, but dcSSc usually accounts for about 30–40% and lcSSc about 60–70%. Asian patients, including Koreans, are characterized by a higher proportion of lcSSc and frequent coexisting ILD. dcSSc shows rapid skin progression and severe visceral involvement within the first few years of onset, whereas lcSSc follows a slowly progressive course over decades.

Epidemiology in Korea: According to Health Insurance Review & Assessment Service (HIRA) data, the number of patients treated for systemic sclerosis was estimated at about 5,000–6,000 as of 2022, and patients registered for rare disease Special Copayment Reduction (V138) are fewer. In a Korean multicenter prospective cohort (KOrea Systemic sclerosis Cohort, KOSC), the rate of coexisting ILD in anti-Scl-70-positive patients is reported at about 60% or more, and PAH is observed in about 10–15%. Korean patients also show female predominance (about 80% or more) and peak onset in the 30s–50s, similar to the West. Many patients with systemic sclerosis are thought to be undiagnosed, and it is not uncommon for patients to first present with Raynaud phenomenon and be diagnosed with systemic sclerosis years later, so strengthening of early diagnosis systems is needed.

Comorbidities: Osteoporosis, depression, anxiety disorders, and nutritional deficiency are common in patients with systemic sclerosis. Cardiovascular risk factors (hypertension, diabetes, dyslipidemia) are also similar to or more common than in the general population, which is interpreted as an effect of chronic inflammation and steroid use. Overlap with other autoimmune diseases such as autoimmune thyroid disease, primary biliary cirrhosis (PBC), and Sjögren syndrome is also frequently observed. There are reports that the overall risk of malignancy is slightly increased in patients with systemic sclerosis, with particularly high relative risks for lung cancer, esophageal cancer, and lymphoma.


5. Pathophysiology

The pathogenesis of systemic sclerosis is a complex process in which three pathological axes—vascular injury, autoimmune activation, and fibrosis—mutually reinforce one another to induce systemic fibrosis. Which of these three axes starts first has not been fully elucidated, but vascular endothelial injury is considered the earliest event.

Vascular injury and abnormal vascular responses: The pathology begins when an unknown initial stimulus (infection, environmental toxin, mechanical injury) damages vascular endothelial cells. Injured endothelial cells increase expression of adhesion molecules (ICAM-1, VCAM-1, E-selectin), attracting monocytes and T cells to the vessel wall. At the same time, the balance of vasoactive substances is disrupted, creating an imbalance of vasoconstriction (increased endothelin-1) versus vasodilation (decreased nitric oxide, prostacyclin). Endothelial injury promotes platelet activation, and platelet-derived TGF-β and PDGF stimulate fibrosis. As capillaries are progressively lost (rarefaction), tissue ischemia persists, which leads to VEGF secretion via hypoxia-inducible factor (HIF-1α), but abnormal new vessels form instead of normal angiogenesis.

Immune activation and autoimmunity: Exposure to vascular endothelial antigens and activation of innate immunity (pattern recognition receptors, TLR signaling) stimulate dendritic cells to initiate adaptive immunity. CD4+ T cells are polarized toward a Th2 phenotype and secrete IL-4 and IL-13, and these cytokines directly activate fibroblasts. IL-17 secreted by Th17 cells also contributes to promoting fibrosis. There is also evidence that reduced function of regulatory T cells (Treg) contributes to the breakdown of immune tolerance. B cells produce autoantibodies, and some autoantibodies, such as anti-Scl-70 antibodies, may directly cause cell injury or transmit fibrotic signals. The interferon signaling pathway (increased expression of type I interferon signature genes) is clearly observed in the blood and skin in systemic sclerosis, an immunopathology shared with lupus.

Mechanisms of fibrosis: TGF-β1/TGF-βR signal transduction is the core fibrotic pathway. TGF-β phosphorylates SMAD2/3, moving them into the nucleus, and activates transcription of the genes for collagen (COL1A1, COL1A2), fibronectin (FN1), and tissue inhibitors of metalloproteinases (TIMP), while suppressing expression of matrix metalloproteinases (MMP), thereby reducing ECM degradation. SMAD-independent pathways (ERK, PI3K/Akt, Wnt/β-catenin) are also involved in maintaining fibrosis. Activated fibroblasts differentiate into myofibroblasts, expressing α-SMA (α-smooth muscle actin), with increased contractility and ECM production capacity. In systemic sclerosis, fibroblasts are in a state of epigenetic memory in which they persistently maintain an activated phenotype, forming a self-perpetuating fibrotic circuit.


6. Symptoms

The clinical symptoms of progressive systemic sclerosis span multiple organs, including the skin, blood vessels, digestive tract, lungs, heart, and kidneys, and the pattern of manifestation and rate of progression differ according to clinical subtype (dcSSc vs. lcSSc) and autoantibody type.

Raynaud's phenomenon: It occurs in more than 90% of patients with systemic sclerosis and in many cases appears years to decades before other symptoms. On exposure to a cold environment or emotional stress, the fingers (sometimes the toes, nose, ears) show a triphasic color change of pallor (white) → blue (cyanosis) → flushing (red). In systemic sclerosis, unlike primary Raynaud phenomenon, it is accompanied by capillaroscopy abnormalities, and persistent ischemia can progress to ischemic fingertip ulcers, digital pitting scars, and in severe cases fingertip gangrene.

Skin symptoms: In dcSSc, skin sclerosis starts in the fingers (sclerodactyly) and spreads rapidly to the hands, forearms, arms, face, and trunk. Early on, edematous changes of the fingers and backs of the hands (puffy hands) appear, followed by progression of increased skin thickness, sclerosis, and pigment changes (hyperpigmentation, depigmentation). Sclerosis of the facial skin causes reduced glabellar wrinkles, radial furrows around the mouth (perioral furrowing), limited mouth opening (microstomia), and narrowing of the nasal alae. Telangiectasia appears on the fingers, face, lips, and tongue and is prominent in lcSSc and CREST syndrome.

Gastrointestinal symptoms: The digestive tract is the most commonly involved internal organ, with gastrointestinal involvement at some site occurring in about 80–90% of patients. Atrophy of esophageal smooth muscle and impaired lower esophageal sphincter function cause gastroesophageal reflux disease (GERD), dysphagia (especially for solid food), and esophageal dilation. Early satiety, nausea, and vomiting may occur owing to delayed gastric emptying (gastroparesis). Small bowel involvement causes diarrhea, malabsorption, weight loss, and nutritional deficiency due to bacterial overgrowth. Colonic sclerosis causes constipation, fecal incontinence, and rarely colonic pseudo-obstruction.

Pulmonary symptoms: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the main causes of systemic sclerosis-related morbidity and mortality. ILD is particularly common in anti-Scl-70-positive dcSSc patients (about 70%), and the early symptoms are slowly progressive exertional dyspnea and dry cough. PAH is more common in lcSSc and CREST syndrome and presents with exertional dyspnea, fatigue, chest pain, and syncope. The two conditions can coexist, so right heart catheterization is needed to differentiate them.

Renal symptoms (scleroderma renal crisis): Scleroderma renal crisis (SRC) is an emergency combining sudden hypertension (malignant hypertension), an abrupt rise in serum creatinine, and microangiopathic hemolytic anemia. It occurs mainly in patients with dcSSc and anti-RNAP III antibody positivity, and high-dose corticosteroid use can be a precipitating factor. Early recognition and immediate administration of an ACE inhibitor are key to recovery of renal function.


7. Signs

The physical signs of systemic sclerosis vary according to the organs involved and the stage of disease, and there are characteristic findings that allow early diagnosis through skilled examination.

Skin and peripheral vascular signs: The degree of skin sclerosis is semi-quantitatively scored from 0 to 3 at 17 body sites using the modified Rodnan Skin Score (mRSS) (maximum total 51 points). When skin sclerosis extending proximal to the MCP joints of both hands is confirmed, it is given the highest weight (9 points) in the 2013 ACR/EULAR classification criteria. Sclerodactyly is a sign in which the fingers become thin and hard with joint flexion contractures. The fingertips show ischemic ulcers, pitting scars, and rarely fingertip necrosis·amputation. On nailfold capillaroscopy, abnormal capillaries (dilation, giant capillaries, hemorrhages, capillary loss) are key evidence for early diagnosis. Telangiectasias are visible to the naked eye on the skin, mucosa, and face and blanch transiently when pressed with a finger and released.

Oral and facial signs: Limited mouth opening (interincisal distance < 4 cm) causes difficulty chewing and difficulty with dental treatment. Radial furrows around the mouth (perioral rhytides) and atrophy of the nasal alae produce a 'mask-like facies' in which the face looks stiff and expressionless. Ocular involvement may be accompanied by dry eye (keratoconjunctivitis sicca), which is prominent especially when Sjögren syndrome overlaps.

Lung auscultation findings: In ILD, dry crackles called 'Velcro' crackles (fine crackles) are heard on inspiration at both lung bases. In PAH, accentuation and splitting of the pulmonic valve closure sound (P2) are characteristic, and with progression, findings of right heart failure (jugular venous distension, lower-extremity edema, hepatomegaly) appear.

Laboratory and instrumental findings: ANA is positive in about 95% of patients, and subtype-specific autoantibodies such as anti-Scl-70 (anti-topoisomerase I) antibodies (diffuse, ILD), anti-RNAP III antibodies (skin progression, renal crisis), anti-fibrillarin/U3-RNP antibodies (heart·lung), anti-PM-Scl antibodies (myositis overlap), and anti-Th/To antibodies (lcSSc, PAH) are used for diagnosis and prognostic prediction. On pulmonary function testing (PFT), a restrictive pattern (reduced FVC·TLC, reduced DLCO) suggests ILD, and an isolated reduction in DLCO suggests PAH. On chest HRCT, the nonspecific interstitial pneumonia (NSIP) pattern (ground-glass opacities, fine reticular opacities, lower-lobe basal predominance) is the most common. On echocardiography, an estimated pulmonary artery systolic pressure (sPAP) ≥ 40 mmHg is the screening criterion for PAH, and confirmation is by right heart catheterization.

Musculoskeletal signs: Arthralgia, finger flexion contractures, and tendon friction rubs may appear. Tendon friction rubs are identified with a stethoscope or by direct palpation around the forearms, ankles, and knees and suggest a poor prognosis in dcSSc. When inflammatory myopathy overlaps, proximal muscle weakness and elevated muscle enzymes (CK, LDH) appear.


8. Screening

Progressive systemic sclerosis is known to take an average of 5–7 years from symptom onset to confirmed diagnosis, so early screening strategies are key to preventing organ damage. In particular, Raynaud phenomenon is the earliest symptom of systemic sclerosis, and systematic screening is needed in patients with Raynaud phenomenon.

Screening for secondary causes in patients with Raynaud phenomenon: Distinguishing primary Raynaud phenomenon (Raynaud disease) from secondary Raynaud phenomenon such as systemic sclerosis is the first step in early diagnosis. Onset after age 40, asymmetric·severe attacks, fingertip ulcers·gangrene, finger swelling, capillaroscopy abnormalities, and autoantibody positivity are red-flag findings suggesting a secondary cause. Nailfold capillaroscopy is a noninvasive screening tool that identifies the pattern specific to systemic sclerosis (SD pattern: giant capillaries, hemorrhages, capillary loss) and is included in the 2013 ACR/EULAR criteria for early diagnosis of systemic sclerosis.

Autoantibody screening: In patients with Raynaud phenomenon or skin changes, ANA is performed first, and when ANA is positive (≥1:80) or systemic sclerosis is clinically suspected, systemic sclerosis-specific autoantibodies (anti-Scl-70, anti-RNAP III, anti-centromere, anti-fibrillarin, anti-PM-Scl, anti-Th/To) are checked. Autoantibody testing corresponds to a 3-point item in the 2013 ACR/EULAR classification criteria and is essential for early diagnosis and prediction of organ involvement. In anti-Scl-70-positive individuals, ILD screening (PFT, HRCT) is performed immediately, and in anti-RNAP III-positive individuals, monitoring of renal function is intensified.

Screening for visceral involvement: ILD screening: pulmonary function tests (FVC, DLCO) at diagnosis regardless of symptoms, and thereafter PFT annually or with clinical change. Chest HRCT is performed when DLCO < 70% or ILD is suspected. PAH screening: annual echocardiography (estimated sPAP measurement, assessment of right heart function) and DLCO. The European DETECT algorithm combines 6 noninvasive variables (FVC/DLCO ratio, BNP, electrical axis, etc.) to determine the indication for right heart catheterization. Gastrointestinal: with symptoms of dysphagia, reflux, or abdominal distension, esophageal manometry, upper GI endoscopy, and GI transit studies are performed. Kidney: blood pressure, creatinine, and proteinuria are checked at every visit, and patients at high risk of renal crisis (early dcSSc, anti-RNAP III positive) are taught home blood pressure monitoring.

Concept of early systemic sclerosis (early SSc): The preliminary criteria of LeRoy and Medsger in 2011 defined the triad combination of capillaroscopy abnormalities, Raynaud phenomenon, and systemic sclerosis-specific autoantibodies as 'early systemic sclerosis'. This concept was also reflected in the 2013 ACR/EULAR criteria, enabling screening even at a stage when skin sclerosis is not yet present. Evidence is accumulating that active surveillance for organ involvement and therapeutic intervention after early recognition can improve long-term prognosis.


9. Diagnosis

Diagnosis of progressive systemic sclerosis is based on the classification criteria jointly published by the ACR/EULAR in 2013. These criteria score various findings of skin, vascular, immunological, and visceral involvement and classify a patient as having systemic sclerosis when the total score is 9 or more.

Main items of the 2013 ACR/EULAR classification criteria: ① Skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints (MCP): 9 points (sufficient) ② Skin thickening of the fingers: distal to MCP to fingertips 4 points, fingertips only 2 points ③ Fingertip lesions: ulcers 2 points, pitting scars 3 points ④ Telangiectasia: 2 points ⑤ Abnormal nailfold capillaries: 2 points ⑥ Pulmonary arterial hypertension or interstitial lung disease: 2 points each (maximum 2 points) ⑦ Raynaud phenomenon: 3 points ⑧ Systemic sclerosis-related autoantibodies (anti-Scl-70, anti-centromere, anti-RNAP III): 3 points. A total of 9 points or more meets the classification criteria. These criteria have a sensitivity of 91% and specificity of 92%, a large improvement over the 1980 ACR preliminary criteria (sensitivity 75%, specificity 73%).

Main differential diagnoses: Differentiation is needed from diffuse eosinophilic fasciitis (Shulman syndrome), nephrogenic systemic fibrosis (NSF) associated with renal failure, graft-versus-host disease (GVHD), drug-induced scleroderma (bleomycin, taxanes), primary Raynaud disease, mixed connective tissue disease (MCTD), and lupus. MCTD is anti-U1-RNP antibody positive, with overlapping features of systemic sclerosis, lupus, and polymyositis. Asymmetric or localized skin sclerosis suggests localized scleroderma (morphea, linear scleroderma), without systemic involvement.

Initial evaluation after diagnosis: As a baseline assessment of organ involvement after confirmation, the following are performed: ① lungs: PFT (FVC, FEV1, DLCO), chest HRCT, 6-minute walk test ② heart: ECG, echocardiography (sPAP, left and right heart function) ③ kidneys: creatinine, GFR, urinalysis ④ digestive tract: esophageal manometry·endoscopy·gastric emptying scan according to symptoms ⑤ skin: mRSS, photographic documentation ⑥ vessels: capillaroscopy ⑦ musculoskeletal: assessment of joint function·muscle strength. This initial evaluation becomes the reference point for subsequently monitoring treatment response and progression.

Subtype classification: According to the LeRoy criteria, patients are classified by extent of skin sclerosis into dcSSc (diffuse cutaneous systemic sclerosis: sclerosis proximal to the MCP joints, extending to the trunk) and lcSSc (limited cutaneous systemic sclerosis: sclerosis distal to the MCP joints, including CREST syndrome). Adding the autoantibody profile makes clinical prognostic prediction more accurate. dcSSc shows rapid visceral involvement and skin progression within 5 years of onset, whereas lcSSc progresses slowly over decades but carries a higher risk of PAH.


10. Treatment

There is as yet no curative treatment for progressive systemic sclerosis, and the goals of treatment are suppression of progression of organ involvement, symptom relief, prevention of complications, and improvement of quality of life. The principle of treatment is an organ-specific approach tailored to each type of skin and visceral involvement.

Raynaud phenomenon and vascular symptoms: Nonpharmacological measures (cold avoidance, warm clothing, smoking cessation) are fundamental. In drug therapy, calcium channel blockers (CCB, especially nifedipine, amlodipine) are the first choice and reduce the frequency and severity of attacks. PDE-5 inhibitors (sildenafil, tadalafil) are effective for severe Raynaud phenomenon and ischemic ulcers. Bosentan (endothelin receptor antagonist) is indicated for prevention of new digital ulcers. There is also small-scale evidence that fluoxetine (SSRI class) helps Raynaud phenomenon. Vasodilating surgery (sympathectomy) is considered in extreme cases.

Interstitial lung disease (ILD): Mycophenolate mofetil (MMF, 2,000–3,000 mg/day) is currently recommended as the first-line immunosuppressant for ILD. In Scleroderma Lung Study I·II, MMF showed an FVC-preserving effect similar to cyclophosphamide with less toxicity. Nintedanib (2×150 mg/day) is an antifibrotic approved by the FDA for SSc-ILD in 2019; in the SENSCIS clinical trial it reduced the rate of FVC decline by about 44%. Combination of MMF and nintedanib is considered. Autologous hematopoietic stem cell transplantation (ASCT, SCOT/ASTIS/ASSIST clinical trials) has been shown to improve survival and organ function in patients with early dcSSc and severe ILD and is considered an option in selected young patients. High-dose corticosteroids are avoided as much as possible because of the risk of renal crisis, and when unavoidable, the minimum dose (≤10 mg/day prednisone) is used.

Pulmonary arterial hypertension (PAH): The diagnosis is confirmed by right heart catheterization (mean PAP ≥ 25 mmHg, PCWP ≤ 15 mmHg, PVR ≥ 3 Wood units). For treatment, combination therapy after risk stratification is recommended. Endothelin receptor antagonists (ERA: ambrisentan, macitentan, bosentan), PDE-5 inhibitors (sildenafil, tadalafil), riociguat (sGC stimulator), and prostacyclin analogs (epoprostenol, iloprost, selexipag) are available. In the AMBITION clinical trial, initial combination of ambrisentan+tadalafil showed a superior reduction in clinical failure compared with monotherapy. Because SSc-PAH has a poorer prognosis than idiopathic PAH, early intensive treatment is important.

Skin fibrosis: Methotrexate (MTX, 15–25 mg weekly) has evidence for suppressing progression of skin sclerosis in early dcSSc. MMF has also been partly reported to improve skin scores. Rituximab (anti-CD20 monoclonal antibody) has some clinical evidence for stabilizing skin scores and ILD in anti-Scl-70-positive dcSSc patients. Tocilizumab (IL-6 receptor antagonist) showed an effect in suppressing FVC decline in the phase 3 focuSSced clinical trial, and its clinical use is expanding.

Scleroderma renal crisis: The standard treatment is immediate administration of an ACE inhibitor (captopril is the most studied) to control blood pressure stepwise. ACE inhibitors are continued even when dialysis is needed, and renal function may recover after several months in some patients. ARBs are not recommended as substitutes for ACE inhibitors. Prophylactic administration of ACE inhibitors to prevent renal crisis is not recommended.

Gastrointestinal involvement: Proton pump inhibitors (PPI) are given long term for GERD and esophageal reflux. Prokinetics such as domperidone and metoclopramide are used for delayed gastric emptying. For bacterial overgrowth, rotating antibiotic therapy (alternating ampicillin, metronidazole, doxycycline) is given. Enteral or parenteral nutritional support is needed for severe malabsorption.


11. Prognosis

The prognosis of progressive systemic sclerosis varies greatly according to clinical subtype, autoantibody type, extent of visceral involvement, timing of diagnosis, and other factors. Overall, it is one of the autoimmune rheumatic diseases with the highest mortality, and management at an appropriate multidisciplinary specialized treatment center is key to improving survival.

Survival and causes of death: The 5-year survival of dcSSc is reported at about 70–80% and 10-year survival at about 55–70%, poorer than lcSSc. The main causes of systemic sclerosis-related death are ILD (about 35%), PAH (about 25%), cardiac involvement (about 15%), and renal involvement (scleroderma renal crisis, about 5%). PAH alone shows the most rapid deterioration among systemic sclerosis-related deaths; median survival after diagnosis was 3–5 years, but it has improved somewhat after the introduction of the latest targeted therapies. In ILD patients, FVC < 70% predicted and DLCO < 40% predicted are poor prognostic indicators.

Prognosis by autoantibody: Anti-Scl-70 (anti-topoisomerase I) antibody positive: diffuse skin involvement, severe ILD, poor survival. Anti-RNAP III antibody positive: rapid skin progression, high risk of scleroderma renal crisis, common in dcSSc; however, skin involvement tends to stabilize later. Anti-centromere antibody (ACA) positive: lcSSc, ischemic fingertip complications, PAH risk; relatively good survival. Anti-fibrillarin (U3-RNP) antibody positive: severe skin involvement, pulmonary hypertension, cardiac involvement; poor prognosis.

Disease activity monitoring: Follow-up integrates the European Scleroderma Study Group (EScSG) disease activity score, the Medsger severity score, changes in mRSS (natural decline in some patients after peaking within 3–5 years of onset), trends in pulmonary function (FVC, DLCO), and changes in echocardiographic sPAP. A decrease in FVC of 10% or more or in DLCO of 15% or more within 12 months is judged to be clinically meaningful ILD progression, and treatment is intensified.

Quality of life: Chronic pain, sleep disturbance, gastrointestinal symptoms, depression, and anxiety greatly reduce quality of life. Reduced functional performance (hand function, walking ability), limitation of occupational activity, and social isolation are also important problems. Integrated management by a multidisciplinary team (rheumatology, pulmonology, cardiology, gastroenterology, nephrology, physical therapy, occupational therapy, mental health) is essential for improving quality of life.


12. Prevention

There is currently no way to prevent the onset of progressive systemic sclerosis itself, and the focus of prevention consists of three stages: ① reducing exposure to risk factors, ② preventing organ damage through early detection, and ③ suppressing the progression of complications in patients who already have the disease.

Primary prevention (prevention of onset): Occupational health management that minimizes exposure to occupational silica dust, organic solvents (trichloroethylene, toluene, xylene), and aromatic amines is important. Workers in high-risk occupations such as mining, quarrying, construction, and ceramics manufacturing wear appropriate protective equipment and undergo regular medical surveillance. Because smoking worsens Raynaud phenomenon and vascular complications, smoking cessation education is essential. Because there are studies suggesting that vitamin D deficiency, which affects immune regulation, may be related to systemic sclerosis, maintaining adequate vitamin D levels is recommended.

Secondary prevention (early detection): In adults with new-onset Raynaud phenomenon, especially onset after age 40, predominant involvement of the fingers of one hand, or accompanying tissue damage, secondary causes including systemic sclerosis must be evaluated. Performing ANA, systemic sclerosis-specific autoantibody tests, and nailfold capillaroscopy is the core of the early diagnosis algorithm. When a family member has an autoimmune disease, early referral to a rheumatologist is recommended when symptoms appear. In patients meeting the early SSc criteria, screening tests for organ involvement are performed every 6–12 months.

Tertiary prevention (prevention of complications): In confirmed patients, the core measures are regular PFT and HRCT to prevent ILD progression, annual echocardiography for early detection of PAH, home blood pressure monitoring to prevent renal crisis, and intensified surveillance in high-risk situations (during high-dose steroid administration). Cold avoidance and keeping warm (gloves, warm clothing) reduce the frequency and severity of Raynaud attacks. Regular dental care (to prepare for difficulty with dental care due to limited mouth opening), physical therapy (maintaining joint range of motion, maintaining hand function), occupational therapy, and nutritional counseling are provided in an integrated manner. Before prescribing, all drugs are reviewed for vascular or renal toxicity, and especially in dcSSc patients the steroid dose is minimized to reduce the risk of renal crisis.


13. References

  1. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-2747. DOI: 10.1002/art.38098. PMID: 24122180.

  2. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. DOI: 10.1016/S0140-6736(17)30933-9. PMID: 28413064.

  3. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease (SENSCIS). N Engl J Med. 2019;380(26):2518-2528. DOI: 10.1056/NEJMoa1903076. PMID: 31112379.

  4. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease (SLS I). N Engl J Med. 2006;354(25):2655-2666. DOI: 10.1056/NEJMoa055120. PMID: 16790698.

  5. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma (SCOT). N Engl J Med. 2018;378(1):35-47. DOI: 10.1056/NEJMoa1703327. PMID: 29298160.

  6. Galie N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. DOI: 10.1183/13993003.01889-2018. PMID: 30545972.

  7. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (focuSSced). Lancet Respir Med. 2020;8(10):963-974. DOI: 10.1016/S2213-2600(20)30248-4. PMID: 32640245.

  8. Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1:15002. DOI: 10.1038/nrdp.2015.2. PMID: 27189141.

  9. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66(6):754-763. DOI: 10.1136/ard.2006.062901. PMID: 17234652.

  10. Kim GT, Kim J, Lee J, et al. Clinical features and organ damage in Korean patients with systemic sclerosis: results from the Korean Systemic Sclerosis Registry. J Korean Med Sci. 2021;36(10):e75. DOI: 10.3346/jkms.2021.36.e75. PMID: 33724741.